Genomic landscape of metastatic colorectal cancer

Josien C. Haan, Mariette Labots, Christian Rausch, Miriam Koopman, Jolien Tol, Leonie J. M. Mekenkamp, Mark A. van de Wiel, Danielle Israeli, Hendrik F. van Essen, Nicole C. T. van Grieken, Quirinus J. M. Voorham, Linda J. W. Bosch, Xueping Qu, Omar Kabbarah, Henk M. W. Verheul, Iris D. Nagtegaal, Cornelis J. A. Punt, Bauke Ylstra, Gerrit A. Meijer

Research output: Contribution to journalArticleAcademicpeer-review

51 Citations (Scopus)


Response to drug therapy in individual colorectal cancer (CRC) patients is associated with tumour biology. Here we describe the genomic landscape of tumour samples of a homogeneous well-annotated series of patients with metastatic CRC (mCRC) of two phase III clinical trials, CAIRO and CAIRO2. DNA copy number aberrations of 349 patients are determined. Within three treatment arms, 194 chromosomal subregions are associated with progression-free survival (PFS; uncorrected single-test P-values <0.005). These subregions are filtered for effect on messenger RNA expression, using an independent data set from The Cancer Genome Atlas which returned 171 genes. Three chromosomal regions are associated with a significant difference in PFS between treatment arms with or without irinotecan. One of these regions, 6q16.1-q21, correlates in vitro with sensitivity to SN-38, the active metabolite of irinotecan. This genomic landscape of mCRC reveals a number of DNA copy number aberrations associated with response to drug therapy
Original languageEnglish
Article number5457
Pages (from-to)5457
JournalNature communications
Publication statusPublished - 2014

Cite this